-
Mashup Score: 130Home Page: Radiotherapy and Oncology - 10 day(s) ago
With over 9,000 members inside and outside Europe, ESTRO supports all the Radiation Oncology professionals in their daily practice: Radiation Oncologists, Medical Physicists, Radiobiologists and RTTs (Radiation TherapisTs) and the wider oncology community. ESTRO’s mission is to promote innovation, research, and dissemination of science through its congresses, special meetings, educational courses and publications. Technical Innovations & Patient Support in Radiation Oncology is an international, open
Source: www.thegreenjournal.comCategories: General Medicine NewsTweet
-
Mashup Score: 7ESTRO/EANO recommendation on reirradiation of glioblastoma - 2 month(s) ago
Reirradiation of brain tumors has a long history of preclinical and clinical studies especially with regards to effectiveness and safety in the recurrent setting. Clinical benefit for reirradiation of brain tumors with data from individual case series dates back more than 80 years [1]. In a recent systematic review by the European Society of Radiotherapy and Oncology (ESTRO) and the European Organization for Research and Treatment of Cancer (EORTC) of 439 studies conducted from 2000 to 2020 on reirradiation, 117 (24 %) involved the brain, and most of them included patients with high-grade gliomas [2].
Source: www.thegreenjournal.comCategories: General Medicine NewsTweet-
Comentado ahora en #ESTRO25 ESTRO/EANO recommendation on reirradiation of glioblastoma - Radiotherapy and Oncology https://t.co/coJIOUAp89
-
-
Mashup Score: 4Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose–response relationship - 2 month(s) ago
To evaluate renal dysfunction after stereotactic ablative body radiotherapy (SABR) for inoperable primary renal cell carcinoma (RCC) using nuclear medicine assessments.
Source: www.thegreenjournal.comCategories: General Medicine NewsTweet-
RT @FREELANCEROG: ficha #RADBIOEDGE #SBRT #RCC #KCSM https://t.co/1dMBE8GC3q https://t.co/NljXBRMhkC
-
-
Mashup Score: 14Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX): Two-Year primary outcome analysis - 2 month(s) ago
In the United States, locally advanced rectal cancer has traditionally been treated with preoperative chemoradiotherapy (CRT) followed by Total Mesorectal Excision (TME) and adjuvant chemotherapy [1]. Despite excellent local control, rates of distant metastasis in this population can exceed 25 % [2–4]. Patients who achieve a clinical complete response (cCR) after neoadjuvant therapy may be safely observed via an organ preservation strategy instead of TME [5–13], which can be associated with sexual, urinary, bowel dysfunction, and/or permanent ostomy [14–16].
Source: www.thegreenjournal.comCategories: General Medicine NewsTweet-
A bit late to posting but excited that our 2 yr Primary Outcomes report for the SHORT-FOX trial is now out in @RO_GreenJournal! https://t.co/3LfcW1WuPD
-
-
Mashup Score: 4‘Plan of the day’ adaptive radiotherapy for bladder cancer using helical tomotherapy - 3 month(s) ago
This study assessed the potential of tomotherapy based Image Guided Radiotherapy (IGRT) to increase the accuracy of bladder irradiation using a ‘plan of the day’ adaptive radiotherapy (ART) technique.
Source: www.thegreenjournal.comCategories: General Medicine NewsTweet-
RT @mirrorsmed: ‘Plan of the day’ adaptive radiotherapy for bladder cancer using helical tomotherapy https://t.co/eCpiuUmQLc Study evalua…
-
-
Mashup Score: 91-year efficacy results after MR-guided risk-adapted stereotactic radiotherapy of infra-diaphragmatic oligometastases in a multicenter phase II trial - 5 month(s) ago
During the last decade, several research groups have succeeded in recruiting to randomized controlled trials and reported the outcome of the use of stereotactic ablative radiotherapy (SABR) in patients with oligometastatic disease (OMD) [1–6]. Large variations exist in reported outcomes among published series, and patient selection plays an important part in this variation [7]. Evidence indicates that treating lesions with a radiotherapeutic definitive intent in the abdominal region is associated with worse outcomes, including increased toxicity and decreased local control rates compared to other treatment sites [8–11].
Source: www.thegreenjournal.comCategories: General Medicine News, Hem/OncsTweet-
Paper here @OncoAlert: https://t.co/hmPlxUDODK
-
-
Mashup Score: 81-year efficacy results after MR-guided risk-adapted stereotactic radiotherapy of infra-diaphragmatic oligometastases in a multicenter phase II trial - 5 month(s) ago
During the last decade, several research groups have succeeded in recruiting to randomized controlled trials and reported the outcome of the use of stereotactic ablative radiotherapy (SABR) in patients with oligometastatic disease (OMD) [1–6]. Large variations exist in reported outcomes among published series, and patient selection plays an important part in this variation [7]. Evidence indicates that treating lesions with a radiotherapeutic definitive intent in the abdominal region is associated with worse outcomes, including increased toxicity and decreased local control rates compared to other treatment sites [8–11].
Source: www.thegreenjournal.comCategories: General Medicine News, Hem/OncsTweet-
Paper here @OncoAlert: https://t.co/hmPlxUDODK
-
-
Mashup Score: 12ESTRO/EANO recommendation on reirradiation of glioblastoma - 6 month(s) ago
Reirradiation of brain tumors has a long history of preclinical and clinical studies especially with regards to effectiveness and safety in the recurrent setting. Clinical benefit for reirradiation of brain tumors with data from individual case series dates back more than 80 years [61]. In a recent systematic review by the European Society of Radiotherapy and Oncology (ESTRO) and the European Organization for Research and Treatment of Cancer (EORTC) of 439 studies conducted from 2000 to 2020 on reirradiation, 117 (24 %) involved the brain, and most of them included patients with high-grade gliomas [2].
Source: www.thegreenjournal.comCategories: General Medicine News, Hem/OncsTweet-
RT @to_be_elizabeth: 📌 ESTRO/EANO recommendation on reirradiation of glioblastoma 🧠 https://t.co/7nfnAI6Zlt 👉🏻Reirradiation for GB should…
-
-
Mashup Score: 114Toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer: A secondary analysis of the LUSTRE randomized trial - 6 month(s) ago
Stereotactic body radiotherapy (SBRT) is increasingly used to treat early-stage non-small cell lung cancer (NSCLC) in medically inoperable patients. Excellent rates of local control (87 %-95 %) and overall survival (65–76 %) have been reported, and toxicity rates are generally low [1–4].
Source: www.thegreenjournal.comCategories: General Medicine News, Hem/OncsTweet-
The largest randomized phase III trial evaluating lung SBRT publishes a secondary analysis of 30 patients with ultra central tumors. #radonc https://t.co/VTtynHgMlf https://t.co/l43uX0yLp7
-
-
Mashup Score: 6A systematic review and meta-analysis on the impact of institutional peer review in radiation oncology - 7 month(s) ago
The link between protocol deviations in radiotherapy and worse clinical outcomes, is well documented in several clinical trials [1]. In real-world clinical practice, one of the key strategies employed by centres to prevent errors is peer review. Following the development of a radiation therapy treatment plan, an evaluation is performed by the treating radiation oncologist and typically a medical physicist, that may involve multiple iterations to achieve an acceptable plan. Peer review is another key component of plan evaluation that involves the appraisal by additional radiation oncologists, and potentially other members of the multidisciplinary team.
Source: www.thegreenjournal.comCategories: General Medicine News, General HCPsTweet-
RT @FuenteApolo: A systematic review and meta-analysis on the impact of institutional peer review in #radonc https://t.co/VMcvs5xIOh peer…
-
I am proud to announce that The Green Journal @RO_GreenJournal now has an Impact Factor of 5.3 🎉 This achievement reflects the strength, relevance, and impact of the research we publish in the field of radiation oncology. Submit your best research: https://t.co/XDOfrx6s6T https://t.co/k8Z6D6SbkW